Maciej Głogowski

The Maria Sklodowska-Curie National Research Institute of Oncology

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Maciej Krzakowski

The Maria Sklodowska-Curie National Research Institute of Oncology

Dariusz M. Kowalski

The Maria Sklodowska-Curie National Research Institute of Oncology

Anna Szumera‐Ciećkiewicz

The Maria Sklodowska-Curie National Research Institute of Oncology

Włodzimierz Olszewski

The Maria Sklodowska-Curie National Research Institute of Oncology

Sebastian Szmit

Postgraduate School of Molecular Medicine

Oliwia Głogowska

The Maria Sklodowska-Curie National Research Institute of Oncology

Monika Prochorec–Sobieszek

Instytut Hematologii i Transfuzjologi

M. Zmijewski

The Maria Sklodowska-Curie National Research Institute of Oncology

Katarzyna Zajda

The Maria Sklodowska-Curie National Research Institute of Oncology

Robert A. Wlodarczyk

The Maria Sklodowska-Curie National Research Institute of Oncology

Cooperative Institutions

The Maria Sklodowska-Curie National Research Institute of Oncology

Centrum Onkologii

National Institute of Oncology

Medical University of Warsaw

Medical University of Lublin

Poznan University of Medical Sciences

Guangdong Academy of Medical Sciences

Southern Medical University

National Institute of Public Health

Central Clinical Hospital

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Preoperative rehabilitation in patients with thoracic tumors and borderline abnormal spirometry results: Preliminary report.

Journal of Clinical Oncology (2013)

Oliwia Głogowska Sebastian Szmit Hanna Tchórzewska-Korba Maciej Głogowski

e18529 Background: The role of preoperative pulmonary rehabilitation is unclear. The aim of the study is short-term efficacy of pulmonary rehabilitation in patients with thoracic tumors and borderline abnormal spirometry results before thoracic surgery. Methods: We observed 12 patients (7 women, 5 men) in mean age of 64 (range 46-82) years. Clinical inclusion criteria were: diagnosis of thoracic tumors and reduced values of FEV1 and FVC predicting postoperative complications. Spirometry and 6MWT were chosen for evaluation of lung function and physical performance during rehabilitation. These tests were performed twice during screening phase to eliminate the factors of learning, and were repeated after first and second week of rehabilitation. Pulmonary rehabilitation included two weeks of training on the treadmill with individually selected speed, physiotherapy exercises and breathing training with using of Triflo. Results: The analyses of results of spirometry and 6MWT before and after 2 weeks of pulmonary rehabilitation indicated the significant differences in values of: 1)FEV1 (L): 1,38 ± 0,23 vs 1,61 ± 0,29 (p=0,01) 2) FEV1 (%N): 56,3 ± 13,9 vs 67,8 ± (p=0,007) 3) FVC (L): 2,24 ± 0,37 vs 2,74 ± 0,67 (p=0,03) 4) FVC (%N): 73,5 ± 15,7 vs 91,2 ± 12,7 (p=0,01) 5) 6MWT distance (m): 251 ± 79 vs 310 ± 74 (p=0,003). Although improvement after rehabilitation, 3 patients were disqualified from lobectomy due to unsatisfactory performance status. Another 3 patients experienced complications during perioperative period. Analysis of pulmonary rehabilitation efficacy showed that 6 patients with favourite outcome after thoracic surgery differed significantly in comparing to others. They achieved significantly higher difference in following parameters: 1) FEV1 (L): 0,4 vs 0,06 (p=0,02) 2) FVC (L): 0,91 vs 0,09 (p=0,02) 3) 6MWT distance (m): 93 vs 25 (p=0,016). Conclusions: A two-week pulmonary rehabilitation leads to significant improvement of lung function and physical performance in patients with thoracic tumors and borderline abnormal spirometry results. A clinically significant increase of absolute values of FEV1, FVC and 6MWT distance may indicate a favourite outcome after thoracic surgery.

Cardiothoracic surgery

10.1200/jco.2013.31.15_suppl.e18529

Cite

Citations (0)

Ectopic acromegaly due to growth hormone-releasing hormone producing bronchial carcinoid causing somatotroph hyperplasia and partial pituitary insufficiency

Polskie Archiwum Medycyny Wewnętrznej (2019)

Maria Stelmachowska‐Banaś Maciej Głogowski Alexandre Vasiljevic Véronique Raverot Gérald Raverot

10.20452/pamw.4413

Cite

Citations (6)

TNM classification of cancer

Nowotwory Journal of Oncology (2000)

Maciej Głogowski

Source

Cite

Citations (1)

Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations

Oncology Letters (2017)

Paweł Krawczyk Dariusz M. Kowalski Rodryg Ramlau Ewa Kalinka‐Warzocha Kinga Winiarczyk

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are routinely used to treat non-small cell lung cancer (NSCLC) in patients with common activating mutations of the EGFR gene. The aim of the study was to compare the efficacies of EGFR-TKIs in patients with common (exon 19 deletions and exon 21 p.Leu858Arg) and rare EGFR mutations. A retrospective analysis of 180 NSCLC patients with common (n=167) and rare (n=13) EGFR mutations treated with erlotinib (n=98), gefitinib (n=66) and afatinib (n=16) was performed. EGFR mutations were determined using RT-PCR and the EntroGen EGFR Mutations Analysis kit. Partial and complete response (PR and CR), progression-free survival (PFS), and overall survival (OS) were analyzed. Demographic and clinical factors had no impact on PFS or OS in patients treated with EGFR-TKIs. Erlotinib, gefitinib, and afatinib showed similar efficacies based on treatment response, median PFS, and OS. The type of EGFR mutation had no impact on median OS; however, median PFS was significantly longer in patients with the exon 19 deletion compared to patients with the exon 21 p.Leu858Arg substitution and rare EGFR gene mutations (P=0.013). Patients with common EGFR mutations showed significantly longer median PFS than those with rare EGFR mutations (10 vs. 5 months; P=0.009). Erlotinib, gefitinib, and afatinib show similar efficacies in NSCLC patients with both common and rare EGFR mutations. When undergoing EGFR-TKI treatment, patients with rare EGFR mutations showed similar OS but poorer PFS. Further investigation into the associations between particular rare EGFR mutations and EGFR-TKIs treatment outcomes is required.

Afatinib

10.3892/ol.2017.5980

Cite

Citations (59)

Changes in plasma miR-9, miR-16, miR-205 and miR-486 levels after non-small cell lung cancer resection

Cellular Oncology (2017)

Maria Sromek Maciej Głogowski Magdalena Chechlińska Mariusz Kulińczak Lukasz M. Szafron

10.1007/s13402-017-0334-8

Cite

Citations (65)

Survival in adult osteosarcoma patients after resection of isolated pulmonary metastases —a single-center experience

Oncology in Clinical Practice (2024)

Maciej Głogowski Sebastian Szmit Oliwia Głogowska Iwona Ługowska Łukasz Talarek

Introduction. Data on factors affecting disease recurrence and survival after pulmonary metastasectomy in adult osteosarcoma patients are still limited and inconclusive. Material and methods. The study included 30 consecutive patients from a single institution who underwent resection of isolated osteosarcoma, with follow-up of pulmonary metastases over the period of 15 years between 1997 and 2012. Various perioperative variables were analyzed retrospectively to confirm the prognostic role of pulmonary surgery for overall and progression-free survival after metastasectomy. The multidisciplinary approach was implemented in qualification for repeated thoracic intervention. Results. The overall 5-year survival rate (OS) after metastasectomy was 28% (median 27.5 months) and the 5-year progression-free survival rate (PFS) was 9% (median 6.33 months). Only radical pulmonary resection significantly influenced both OS (HR = 5.41; 95% CI 1.87–15.60, p = 0.002) and PFS (HR = 5.17; 95% CI 1.70–15.68, p = 0.004) after metastasectomy. The efficacy of thoracic surgery was independent of the patient's age, sex, number of operable lung metastases, bilateral presence of lung metastases, or time to the appearance of lung metastases after surgery for osteosarcoma. Five-year OS and PFS after radical and nonradical pulmonary metastasectomy were 35% vs. 0% (p = 0.002) and 11% vs. 0% (p = 0.004), respectively. In the observed group, 60 thoracotomies were performed; 3 or more procedures were needed in 8 (27%) patients. Conclusions. Similar to the population of children and adolescents, radical pulmonary metastasectomy may be a curative treatment strategy in selected adult patientswithmetastatic osteosarcoma. Repeated procedures are necessary in many cases.

Single Center

Center (category theory)

10.5603/ocp.98396

Cite

Citations (0)

Leczenie chirurgiczne niedrobnokomórkowego raka płuca w skojarzeniu z immunoterapią

Maciej Głogowski

Leczenie chirurgiczne raka pluca jest nadal terapią z wyboru u chorych z rozpoznaniem wczesnego niedrobnokomorkowego raka pluca. Chemioterapia neoadjuwantowa i adjuwantowa jest stosowana u chorych w II i III stopniu zaawansowania w skojarzeniu z leczeniem chirurgicznym. Rola leczenia immunoterapią w skojarzeniu z leczeniem chirurgicznym jest nadal przedmiotem badan klinicznych. W artykule dokonano krotkiego przeglądu aktualnych badan klinicznych z uzyciem immunoterapii z leczeniem chirurgicznym wczesnego niedrobnokomorkowego raka pluca.

Cite

Citations (0)

Videothoracoscopic talc poudrage pleurodesis for the treatment of malignant pleural effusions secondary to breast cancer

Journal of Clinical Oncology (2005)

Maciej Głogowski I. Głogowska I. Lemańska M. Zmijewski Tadeusz Pieńkowski

8216 Background: Metastatic breast cancer (mbc) is a most frequent reason of malignant pleural effusion(MPE) in women. The effective treatment of pleural fluid reaccumulation is a important aim in managment and paliative care of patients (pts) with mbc.The aim of this report is to evaluate the results of videothoracoscopic talc poudrage (TPP) pleurodesis secondary to mbc. Methods: Between November 1999 and December 2003, 57 pts with MPE with primary breast cancer uderwent videothoracoscopy (VATS). Clinical symptoms of MPE were observed in all pts and ECOG PS were:1–39pts, 2–16pts,3–2pts. Pleural fluid was a single site of mbc in 8 pts and was the first site of mbc in 24 pts. Median time from radiologic diagnosis to VATS was 34days (r 6–517). Histology of mbc was confirmed in 52pts(91%). Pleurodesis was performed with 5 g of sterile purified talc insufflated through a talc atomizer. One chest tube was left in pleural space until the fluid drainage was less than 200ml per postoperative day. 50pts were treated by systemic therapy after TPP. Results: No perioperative mortality was observed. We noted 7(12%) severe postoperative complications: 3 cases of acute respiratory failure,one case of heart failure one case of renal insufficiency, one case of pulmonary embolism and one case of gastric perforation. Averange hospitalisation was 6 days (3–51). We noted 6 cases of incomplete lung reexpansion (10%).It correlated with long time from radiologic to VATS diagnosis (over 6 mts). 51 pts (90%) had succesful pleurodesis and regresion of symptoms. In this group we observed 3 reccurences of effusion-after 2,3 and 7 mts. After a median follow-up of 10 mts (range 1–37), talc pleurodesis was succesful in controlling recurrence of effusion in 52 pts (91%). 35 pts died as a result of progression of mbc. 22 pts alive without recurrence of effusion. Overall survival (OS) at 6,12 and 24 mts was 65%, 52% and 28% and correlated with number of metastatic sites and PS. We noted better prognosis in pts with single metastatic site in pleura (median survival time 18 vs 8mts, p<0,001). Conclusions: TPP is an effective and safe method of lifelong pleurodesis in pts with mbc. It is able to help efficiency of systemic therapy and supportive care. No significant financial relationships to disclose.

Pleurodesis

Chest tube

10.1200/jco.2005.23.16_suppl.8216

Cite

Citations (0)

Thoracic neoplasms

Oncology in Clinical Practice (2022)

Maciej Krzakowski Jacek Jassem Adam Antczak Katarzyna Błasińska Joanna Chorostowska‐Wynimko

10.5603/ocp.2021.0022

Cite

Citations (7)

Parallel SPR and QCM-D Quantitative Analysis of CD9, CD63, and CD81 Tetraspanins: A Simple and Sensitive Way to Determine the Concentration of Extracellular Vesicles Isolated from Human Lung Cancer Cells

Analytical Chemistry (2023)

Agata Kowalczyk Aleksandra Gajda-Walczak Monika Ruzycka-Ayoush Alicja Targońska Grażyna Mosieniak

Tetraspanins, including CD9, CD63, and CD81, are transmembrane biomarkers that play a crucial role in regulating cancer cell proliferation, invasion, and metastasis, as well as plasma membrane dynamics and protein trafficking. In this study, we developed simple, fast, and sensitive immunosensors to determine the concentration of extracellular vesicles (EVs) isolated from human lung cancer cells using tetraspanins as biomarkers. We employed surface plasmon resonance (SPR) and quartz crystal microbalance with dissipation (QCM-D) as detectors. The monoclonal antibodies targeting CD9, CD63, and CD81 were oriented vertically in the receptor layer using either a protein A sensor chip (SPR) or a cysteamine layer that modified the gold crystal (QCM-D) without the use of amplifiers. The SPR studies demonstrated that the interaction of EVs with antibodies could be described by the two-state reaction model. Furthermore, the EVs' affinity to monoclonal antibodies against tetraspanins decreased in the following order: CD9, CD63, and CD81, as confirmed by the QCM-D studies. The results indicated that the developed immunosensors were characterized by high stability, a wide analytical range from 6.1 × 104 particles·mL–1 to 6.1 × 107 particles·mL–1, and a low detection limit (0.6–1.8) × 104 particles·mL–1. A very good agreement between the results obtained using the SPR and QCM-D detectors and nanoparticle tracking analysis demonstrated that the developed immunosensors could be successfully applied to clinical samples.

CD81

Tetraspanin

CD63

Extracellular Vesicles

10.1021/acs.analchem.3c00772

Cite

Citations (13)